KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $141.7 million.

  • Nektar Therapeutics' Cash from Financing Activities rose 108972307.69% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.0 million, marking a year-over-year increase of 23766.5%. This contributed to the annual value of $42.1 million for FY2024, which is 14029333.33% up from last year.
  • Nektar Therapeutics' Cash from Financing Activities amounted to $141.7 million in Q3 2025, which was up 108972307.69% from $211000.0 recorded in Q2 2025.
  • Nektar Therapeutics' Cash from Financing Activities' 5-year high stood at $141.7 million during Q3 2025, with a 5-year trough of $7000.0 in Q1 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $339000.0 (2022), whereas its average is $13.9 million.
  • Over the last 5 years, Nektar Therapeutics' Cash from Financing Activities had its largest YoY gain of 108972307.69% in 2025, and its largest YoY loss of 9998.33% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Cash from Financing Activities (Quarter) stood at $2.6 million in 2021, then plummeted by 95.96% to $103000.0 in 2022, then crashed by 88.35% to $12000.0 in 2023, then soared by 591.67% to $83000.0 in 2024, then soared by 170595.18% to $141.7 million in 2025.
  • Its Cash from Financing Activities stands at $141.7 million for Q3 2025, versus $211000.0 for Q2 2025 and $7000.0 for Q1 2025.